The Sensium™ disposable digital plaster solution was granted 510(k) approval by the US FDA in July 2011 for use in US hospitals. The Sensium™ is an ultra-low power technology platform that provides unobtrusive, continuous, wireless monitoring of vital signs for up to six days. It provides a wireless link from the patient to the hospital’s electronic information system, allowing wireless monitoring of heart rate, respiration and temperature. The disposable product will be mainly used in hospitals.
During the year Toumaz established a joint venture with CCE, a company owned by Dr Patrick Soon-Shiong, to commercialize the disposable Sensium™ plaster worldwide. The joint venture, Toumaz US, is owned 20% by Toumaz and 80% by CCE. Toumaz will sell Sensium™ chips and boards to the joint venture and receive royalty on sale of all products containing Toumaz IP.
Initial commercial launch in a Los Angeles hospital is imminent. The Sensium™ will be deployed initially to a small number of rooms with a gradual deployment to all general ward beds thereafter.
The Group continues to work to expand the Sensium™ product range to applications outside of hospitals, including non-disposable devices for wireless monitoring in the home and on the move. This includes a non-exclusive license agreement with a newly established company to use Sensium™ technology for sports and fitness applications in the UK.
Quanta Computer has developed a prototype product based on Sensium™ technology targeting diabetes type II sufferers. Prototypes are currently being tested.